Oncoclínicas&Co has a turnover of R$6 billion and a profit of R$313 million in 2023 – 2024-04-02 20:05:09

SÃO Paulo (ots/PRNewswire) – The increase in the number of patients treated and the improvement in operational efficiency explain the record results

Oncoclínicas&Co (B3: ONCO3) – the largest cancer treatment group in Latin America – reported a 35.1% increase in its gross revenues for 2023, totaling R$6.0 billion. This development is primarily due to the increasing number of patients treated, which increased by 26.8% compared to 2022 with around 635,000 procedures. In the fourth quarter of 2023 (4Q23), gross sales reached R$ 1.6 billion, an organic growth of 18.7% compared to the same period in 2022. The company continued to accelerate its growth, not only due to the higher number of patients in its departments , but also due to its various strategic partnerships with health insurance companies and operators, without compromising on excellent patient care.

In 2023, gross profit amounted to R$ 1.9 billion, representing a margin of 35.4%, an increase of 33.7% compared to 2022. EBITDA for the full year was R$1.0 billion (R$1.1 billion excluding the non-cash effect of calculating the long-term incentive plan or on an ex-PILP basis), up 58.9 % above the 2022 value, reflecting not only the company’s revenue growth but also the efficiencies achieved in operations.

This was the sixth consecutive quarter with net profit reaching R$87.0 million in 4Q23. Total net profit for 2023 was R$312.6 million, 174.7% more than in 2022. Net profit excluding the impact of the PILP was R$359.4 million in 2023. The company is now reaping the rewards of its corporate structure rationalization project, which began about two years ago. Enormous progress has also been made in allowing minorities to participate in the bottom line. Net income per share, excluding minority shareholders, increased from R$0.08 per share in 2022 to R$0.40 per share in 2023, an increase of 383.4%.

“These figures reflect our commitment to the company’s principles: use of technology, medical excellence and high specialization, always taking cost-effectiveness into account and constantly striving for improvements in efficiency at the service of our patients, doctors and partners,” emphasizes Bruno Ferrari, founder and CEO of Oncoclinicas&Co.

For more information, see

View original content:

Questions & Contact:

Information for the press: GBR COMMUNICATION: Bruna Narcizo | 11 98813-0111 | bruna.narcizo@gbr.com.br; Olenka Lasevitch | 21 97972-7824 | olenka.lasevitch@gbr.com.br